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Introduction
Molecules of  the human leukocyte immunoglobulin-like receptor (LILR) family, discovered over 2 
decades ago (1, 2), are expressed on leukocytes and are commonly dysregulated in a wide range of  
pathologies (3–5). There are 5 activating (LILRA1, 2, 4–6), 5 inhibitory (LILRB1–5), and 1 soluble (LIL-
RA3) LILR that together regulate immune responses (3). They display 2, or 4, homologous C-2–type 
Ig-like extracellular domains but differ in their transmembrane and cytoplasmic regions (2, 6). LILRA 
have short truncated cytoplasmic tails with charged arginine residues in their transmembrane domains, 
facilitating association with the immunoreceptor tyrosine-based activation motif–bearing Fcε receptor γ 
chain to propagate activating signaling cascades (7). Conversely, LILRB have long cytoplasmic tails that 
contain multiple immunoreceptor tyrosine-based inhibition motifs (ITIMs), which recruit phosphatases 
such as SHP-1 and SHIP-1 to elicit inhibitory signaling (2, 6). Located at human chromosome 19q13.4, 
these receptors demonstrate significant allelic variation, with LILRB3, LILRB4 (ILT3), and LILRA6 
(ILT8) each displaying at least 15 variants (2, 8–10).
The LILRB molecules are proposed to act as immune checkpoints serving to control and limit overt 
immune responses (3). In agreement with this, LILRB expression is increased in suppressive (also referred 
to as alternatively activated or M2) macrophages and tolerogenic dendritic cells (DCs) (11–15). On mono-
cytes, coligation of  LILRB1 (ILT2) and LILRB2 (ILT4) with the activatory Fcγ receptor I (CD64) results 
in SHP-1 activation, decreasing downstream phosphorylation events and intracellular calcium mobiliza-
tion (16). Engagement of  LILRB1 on macrophages by the common HLA-I subunit, β2-microglobulin, on 
malignant cells limits their phagocytic potential (17). Similarly, we and others have shown that ligation 
of  LILRB1, 2, or 4 renders DCs tolerogenic, leading to inhibition of  T cell responses (11, 12, 15, 18–21). 
Despite advances in identifying the key immunoregulatory roles of many of the human leukocyte 
immunoglobulin-like receptor (LILR) family members, the function of the inhibitory molecule 
LILRB3 (ILT5, CD85a, LIR3) remains unclear. Studies indicate a predominant myeloid expression; 
however, high homology within the LILR family and a relative paucity of reagents have hindered 
progress toward identifying the function of this receptor. To investigate its function and potential 
immunomodulatory capacity, a panel of LILRB3-specific monoclonal antibodies (mAbs) was 
generated. LILRB3-specific mAbs bound to discrete epitopes in Ig-like domain 2 or 4. LILRB3 ligation 
on primary human monocytes by an agonistic mAb resulted in phenotypic and functional changes, 
leading to potent inhibition of immune responses in vitro, including significant reduction in T cell 
proliferation. Importantly, agonizing LILRB3 in humanized mice induced tolerance and permitted 
efficient engraftment of allogeneic cells. Our findings reveal powerful immunosuppressive functions 
of LILRB3 and identify it as an important myeloid checkpoint receptor.
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As such, the engagement of  LILRB1 and LILRB2 by their high-affinity ligand HLA-G is an import-
ant immunosuppressive pathway at the fetal-maternal interface during pregnancy (22–24) and may be 
involved in tumor immunoevasion (5).
Although mice do not express LILRs, they possess an orthologous system composed of  2 paired Ig-like 
receptors (PIRs): the activating PIR-A and the inhibitory PIR-B. PIR-B regulates priming of  cytotoxic T 
lymphocytes by DCs through interaction with MHC class I (MHCI) (25) and negatively influences inte-
grin signaling in neutrophils and macrophages (26). Furthermore, PIR-B regulates the differentiation of  
myeloid-derived suppressor cells (MDSCs) that aid tumor progression (27).
Among the inhibitory LILRB molecules, LILRB3 (ILT5/LIR3/CD85a), containing 4 extracellular 
Ig-like domains and 4 cytoplasmic ITIMs, represents an attractive immunomodulatory target because of  
its relative restriction to, and high expression on, myeloid cells (3, 4). However, due to the lack of  specif-
ic reagents and model systems, its exact functions and immunoregulatory potential have not been fully 
explored. In this study, we addressed this by generating a bespoke panel of  novel LILRB3-specific mAbs, 
some of  which were used to probe the function of  LILRB3 in relevant preclinical platforms. Our data 
demonstrate that LILRB3 activation confers potent immunoinhibitory functions through reprograming 
and tolerizing of  myeloid cells and suggest that modulating LILRB3 activity may provide exciting new 
treatment strategies in various disease settings, such as transplantation.
Results
Generation and characterization of  a panel of  fully human LILRB3-specific mAbs. To study the protein expression 
and function of  LILRB3, LILRB3-specific antibodies were identified from a human antibody phage-display 
library, n-CoDeR (28, 29). Initial alignment analysis of  extracellular domains of  LILRB1–5 indicated the 
presence of  a limited number of  conserved amino acid (a.a.) residues across the LILRB3 ectodomain (Sup-
plemental Figure 1; supplemental material available online with this article; https://doi.org/10.1172/jci.
insight.141593DS1), against which specific mAbs could be generated. In this regard, phages binding to the 
“target” ectodomain of  LILRB3 protein (present in solution, coated on a plastic surface, or expressed on 
cells), and not to the homologous (~65% extracellular homology) “nontarget” LILRB1 ectodomain protein, 
were selected (Figure 1A and Supplemental Figure 2). To increase specificity and yield, the cross-reactive 
phages were initially removed through a preselection (negative selection/depletion using “nontarget” pro-
teins), followed by the selection itself  (positive selection). Following each selection round, the selected clones 
were screened against the ectodomains of  both LILRB1 and LILRB2 by fluorometric microvolume assay 
technology (FMAT) and ELISA, and cross-reactive clones were further excluded from the panel. After 3 
rounds of  phage panning and enrichment, successful selection of  clones specific for LILRB3 was reconfirmed 
by FMAT and ELISA, with target-specific phages converted to soluble single-chain variable fragment (scFv) 
and screened further (Figure 1, B and C). Successful clones were selected based on binding to LILRB3 and 
lack of  cross-reactivity to LILRB1 and LILRB2. Selected scFv clones (>200) were then sequenced and tested 
for binding against primary cells and LILRB transfectants using high-throughput flow cytometry (Figure 1D). 
Subsequently, 46 candidate target-specific clones were converted to human IgG1 (hIgG1) and, in addition 
to screening against LILRB1–3 transfectants, to exclude those with potential broader LILR cross-reactivity, 
were screened against a larger panel of  LILR-expressing cell lines (Figure 1E). Due to cross-reactivity to 
one or more other LILR family members, as exemplified by clone A30 (Figure 1E, bottom panel), 30 mAb 
clones were further excluded at this stage. In total a panel of  16 LILRB3-specific antibodies were identified 
for further study. These LILRB3-specific clones were further tested and confirmed to have no cross-reactivity 
to the mouse orthologue, PIR-B (data not shown). A selection of  these mAbs were then fluorochrome labeled 
and used to determine the LILRB3 expression profile on human peripheral blood leukocytes, demonstrating 
predominant staining of  monocytes and to a lesser extent granulocytes (Figure 1, F and G), in agreement with 
previous reports (2, 3, 6). The immunophenotyping also revealed that LILRB3 expression was significantly 
higher on circulatory CD14hiCD16– classical and CD14+CD16lo intermediate monocytes compared with the 
more inflammatory CD14+CD16hi nonclassical monocytes (Figure 1, F and G).
The selected LILRB3 mAbs were also tested for their specific binding properties. Surface plasmon res-
onance (SPR) analysis showed that all LILRB3-specific clones bound to recombinant LILRB3-hFc protein 
in a dose-dependent manner (as represented by A16; Figure 2A) and displayed a range of  affinities (Table 
1). Interestingly, all mAbs had similar association rates (~105) but varied in their dissociation rates by 3 
orders of  magnitude (~10–3 to 10–6).
3insight.jci.org   https://doi.org/10.1172/jci.insight.141593
R E S E A R C H  A R T I C L E
4insight.jci.org   https://doi.org/10.1172/jci.insight.141593
R E S E A R C H  A R T I C L E
Cell surface epitope-mapping studies were then performed and compared with a commercial mAb (clone 
222821), using a series of LILRB3 extracellular domain (D) mutants displaying either all 4 Ig domains (WT), or 
3 domains, 2 domains, or 1 domain, transiently transfected into HEK293F cells. Two distinct groups of mAbs 
were identified: those that bound to the WT, D3-expressing, and D2-expressing cells (including clone 222821 
and exemplified by A12) and those that bound only to the WT-transfected cells (exemplified by A1) (Figure 2B). 
Although conserved a.a. residues were present throughout the ectodomain (Supplemental Figure 1), the select-
ed mAbs were shown to bind within either D2 or D4 (6/16 and 10/16 clones, respectively; Table 1), perhaps 
indicating improved accessibility for these regions within the 3D structure. In agreement with this, subsequent 
blocking assays confirmed that a number of D2-binding mAbs reduced the binding of the commercial mAbs 
(e.g., A12), suggesting shared or related epitopes, while others did not (e.g., A1), confirming binding to discrete 
epitopes (Figure 2C and Table 1).
Subsequently, reporter cells transfected with a chimeric receptor expressing the extracellular domain 
of  LILRB3, fused with the human CD3ζ cytoplasmic domain, were used to investigate whether the gener-
ated mAbs were able to cross-link the receptor. Cross-linking results in the production of  nuclear factor of  
activated T cells activation and the subsequent expression of  GFP and is indicative of  agonistic potential 
(30). Using these cells, we were able to identify 2 distinct groups of  LILRB3 mAbs, those with “agonistic” 
activity capable of  inducing signaling upon binding to the receptor (e.g., A1) and those that were inert (e.g., 
A28) (Figure 2D). Collectively, these data demonstrate that highly specific, fully hIgG1 mAbs were raised 
against LILRB3, amenable to the comprehensive evaluation of  LILRB3 function.
LILRB3 ligation modulates T cell activation and proliferation. Accordingly, using a select number of  mAbs, 
we sought to investigate the immunomodulating effect of  the LILRB3 mAbs on cellular effector functions. 
LILRB1 has previously been shown to directly inhibit T cell responses by causing dephosphorylation of  
the CD3 signaling cascade, and, in addition, has the potential to negatively regulate T cell activation by 
competing with CD8 for HLA-I binding (31, 32). Moreover, LILRBs can indirectly inhibit T cell respons-
es by rendering antigen-presenting cells (APCs), such as monocytes and DCs, tolerogenic (14, 18, 33). 
To investigate the immunomodulatory potential of  LILRB3 and its ability to regulate adaptive immune 
responses, we used a T cell proliferation assay incorporating fresh PBMCs isolated from healthy human 
donors, as before (34). Fcγ receptors (FcγRs) help mediate the effects of  hIgG (35). Therefore, to study the 
direct F(ab′):LILRB3-mediated effects of  the mAb on T cell proliferation, they were first deglycosylated 
to reduce FcγR-IgG interactions. SDS-PAGE showed a decrease in molecular weight of  deglycosylated 
mAbs compared with WT controls, indicative of  successful deglycosylation (Figure 3A). The mAbs were 
then introduced to a T cell proliferation assay where CD3 and CD28 antibodies elicited cell clustering and 
CFSE dilution, indicative of  a significant increase in CD8+ T cell proliferation, compared with nontreated 
controls (Figure 3, B and C). Clone A1, shown to be an agonist (Figure 2D), significantly inhibited CD8+ 
T cell proliferation in this assay when compared with the isotype control (Figure 3, B and C). Similarly, 
the commercial antibody (clone 222821) substantially inhibited T cell proliferation (data not shown). Other 
LILRB3-specific mAbs had either no or subtle effects, as represented by clones A16 and A28. These data 
demonstrate that LILRB3 ligation by agonistic mAbs suppresses T cell responses, whereas other clones 
Figure 1. Generation of fully human mAbs against LILRB3. (A) Schematic of antibody generation by phage-display via 3 independent “panning” techniques; 
(i) immobilized target (LILRB3), (ii) biotinylated target and excess nontarget (LILRB1), and (iii) LILRB3-transfected cell lines (from left to right). Biopanning was 
performed against generated target protein using an scFv library; “nontarget” cross-reactive scFv clones were removed by competition, and target-specific scFv 
clones were then eluted and converted to a soluble format, sequenced, and screened by various cell- and protein-based assays. (B and C) Screening of generated 
LILRB3 clones. (B) FMAT and (C) ELISA were performed and scFv clones screened against LILRB3 target– and LILRB1/LILRB2 nontarget–transfected CHO-S cells 
and extracellular LILRB1 protein, respectively. The relative binding to each target was calculated, with target-specific scFv clones depicted in yellow and the irrel-
evant isotype control shown in green. Nonbinding and cross-reactive scFv clones depicted in blue. (D) Screening of LILRB3 scFv clones by high-throughput flow 
cytometry. PBMCs (left plot) or LILR-transfected CHO-S (middle plot) cells were incubated with His-tagged scFv supernatants, followed by secondary anti-His 
staining. Where transfected CHO-S cells were used, LILRB1- and LILRB2-transfected cells were used as nontargets for LILRB3. Clones were compared against 
both gated CD14+ monocytes and target-transfected CHO-S cells (right plot). LILRB3-specific clones highlighted in yellow, nonspecific or nonbinding clones in 
red, and isotype control in green. (E) Specificity of LILRB3 clones against human LILR-transfected 2B4 cells. LILRB3 mAbs were tested against cells stably trans-
fected with the indicated LILR family members by flow cytometry; a representative specific clone (A16; top panel) and a nonspecific cross-reactive clone (A30; 
bottom panel) are shown. (F–G) Testing the specificity of directly fluorochrome-labeled LILRB3 clones against primary cells by flow cytometry. (F) Fresh whole 
peripheral blood stained with either APC-labeled LILRB3 (represented by clone A16) or an irrelevant human (h) IgG1 isotype control as well as various leukocyte 
surface markers, as indicated. Dot plots and histograms are representative of multiple donors indicating gating of each leukocyte subset as indicated: T cells, B 
cells, NK cells, monocytes, and granulocytes. (G) Graph showing relative expression of LILRB3 on each leukocyte subset. One-way ANOVA test performed (*P < 
0.05; **P < 0.005); n = 5 independent donors (each color represents an individual donor). (E–F) Histogram pink and blue traces indicate staining with irrelevant 
isotype control or LILRB3 mAb, respectively.
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Figure 2. Characterization of LILRB3 antibodies. (A) LILRB3 
mAb affinity assessed by SPR. LILRB3-hFc recombinant 
protein was immobilized, and various LILRB3 mAbs flowed 
across the chip. Representative LILRB3 clone A16 shown. (B) 
LILRB3 domain epitope mapping. HEK293F cells transfected 
with WT LILRB3 (full-length extracellular portion), D1–3, 
D1–2, or D1 were stained with LILRB3 clones, followed by an 
anti-hIgG secondary antibody. Schematic of domain con-
structs and restriction digest of each DNA construct shown 
(top panel). Histograms showing staining of 2 representative 
clones differentially binding to color-coded cells expressing 
WT (D4), D1–3, D1–2, and D1 (bottom panel; n = 3 indepen-
dent experiments). (C) Ability of generated mAbs to cross-
block binding of a commercial LILRB3 mAb (clone 222821). 
PBMCs were stained with unconjugated LILRB3 antibody 
clones and subsequently stained with a directly conjugated 
222821 mAb and analyzed by flow cytometry; representative 
clones displayed (A1 nonblocking; A12 partial blocking), as 
indicated. (D) LILRB3 2B4 reporter cells were incubated with 
10 μg/mL LILRB3 antibodies overnight to assess receptor 
signaling potential as judged by GFP induction measured by 
flow cytometry; representative clones with percentage of 
GFP expression shown (n = 2 independent experiments).
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confer no inhibitory effects. Similar effects were also observed when considering CD3+CD8– T cells (pre-
dominantly CD3+CD4+ T cells; Figure 3C and not shown). There was notable donor variation in the T cell 
proliferation assay, which is partly due to the nature of  this assay and may also reflect differing expression 
levels and/or LILRB3 polymorphic variants present on the myeloid cells — none of  which were formally 
tested here. When the assay was repeated with isolated T cells, no inhibition was seen, confirming that 
APCs within the PBMC mixture, most likely monocytes, were responsible for the effects observed (Sup-
plemental Figure 3), as expected, given the lack of  expression of  LILRB3 on T cells (Figure 1, F and G).
LILRB3 ligation induces immune tolerance in humanized mice. Given these data showing that T cells could be 
suppressed following LILRB3 ligation on myeloid cells, we next investigated the possible effects of  LILRB3 
modulation in an allogeneic engraftment model using humanized mice, previously reconstituted with prima-
ry human fetal hematopoietic stem/progenitor cells (HSPCs) (Figure 4A). Characterization of  peripheral 
blood leukocytes and bone marrow of adult humanized mice demonstrated that LILRB3 was expressed on, 
and restricted to, myeloid cells, but not lymphocytes, similar to humans (Figure 4B and Supplemental Figure 
4). We recently showed that allogeneic human lymphoma cells are readily rejected in humanized mice due to 
HLA mismatch (36). To test the potential of  LILRB3 ligation to suppress the allogeneic immune response, 
adult humanized mice were treated with the agonistic LILRB3 mAb (A1) and the engraftment of  allogeneic 
human B cell lymphoma cells, derived from an unrelated donor (36, 37), was monitored over time (Figure 
4A). LILRB3 mAb treatment was able to induce a state of  tolerance in vivo and led to a successful engraft-
ment of  the donor allogeneic cells (Figure 4C). Accordingly, LILRB3-treated tumor-bearing humanized mice 
subsequently succumbed to disease with high tumor burden, whereas isotype control–treated mice readily 
rejected the lymphoma cells without morbidity (Figure 4D). These observations corroborate our in vitro func-
tional assays and identify LILRB3 as a key regulator of  immune tolerance in an allotransplant setting. Given 
the expression pattern of  LILRB3 on myeloid but not lymphocytic cells in both the human PBMCs and 
humanized mice, we sought to explore the effects of  the LILRB3 mAbs on these cells.
LILRB3 ligation leads to transcriptional modification and M2 skewing of  human APCs. To investigate the path-
ways and factors involved in LILRB3-mediated immunosuppression, we next investigated the transcriptomic 
changes in monocytes following LILRB3 engagement. Short-term (~18-hour) in vitro treatment of  freshly 
isolated human peripheral CD14+ monocytes with the agonistic LILRB3 mAb (A1) caused a dramatic shift in 
their phenotype (Figure 5A), with the cells displaying a significantly more elongated morphology (P < 0.0001) 
Table 1. LILRB3 mAb characterization
Clone ID Ig-like domain Blocking potential Affinity (KD)
1 (A1) 4 N 3.12 × 10–10
2 (A12) 2 Y 5.30 × 10–10
3 4 N 2.92 × 10–10
4 (A16) 4 N 2.88 × 10–9
5 2 Y 1.04 × 10–9
6 2 N 1.55 × 10–9
7 4 N 3.85 × 10–10
8 (A28) 4 N 1.46 × 10–9
9 4 N 9.84 × 10–9
10 2 N 3.71 × 10–10
11 4 N 1.37 × 10–9
12 4 N 1.24 × 10–10
13 4 N 3.25 × 10–9
14 2 N 3.05 × 10–10
15 4 N 1.56 × 10–9
16 2 N 1.68 × 10–8
222821 2 - 1.47 × 10–11
Summary of binding domain, blocking potential, and affinity measurements for the selected LILRB3-specific mAb. 
Clone 222821 represents the commercial LILRB3 mAb (mIgG2a). Ability to block binding of clone 222821 is indicated 
by yes (Y) or no (N). Affinity assessed using the univalent model of 1:1 binding by SPR; clone IDs described herein are 
indicated in parentheses.
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resembling immunosuppressed M2 macrophages (38). In accordance with this, RNA-Seq analysis revealed 
that ligation of  LILRB3 on monocytes induced a signature resembling “M2-skewed” immunosuppressive 
macrophages (Figure 5B). Concurrently, the expression of  genes associated with “M1-skewed” immunostim-
ulatory macrophages was downregulated in LILRB3-ligated monocytes (Figure 5, B and C). These data were 
confirmed by quantitative PCR (qPCR) for a number of  the differentially regulated genes on a further 6 
donors (Figure 5D). As further evidence, we showed that the effects were dependent upon LILRB3 agonism 
because treatment of  monocytes with a nonagonistic LILRB3 mAb (A28), despite binding the same domain, 
did not affect monocyte phenotype or gene expression (Figure 5D). Gene set enrichment analysis (GSEA) of  
the RNA-Seq data showed a positive correlation with gene signatures reported for suppressive macrophages, 
e.g., oxidative phosphorylation (39). Conversely, LILRB3-ligated monocyte gene signatures negatively cor-
related with those reported for inflammatory macrophages, e.g., IFN-γ and IFN-α responsive elements, as 
well as allograft rejection (Figure 5E), in line with our in vivo observations (Figure 4). In summary, these 
Figure 3. LILRB3 ligation regulates T cell activation and proliferation. CFSE-labeled PBMCs were stimulated with antibodies against human CD3 
(0.02 μg/mL) and CD28 (5 μg/mL) in the presence or absence of isotype control (iso ctrl) or LILRB3 mAb (10 μg/mL) and proliferation measured 
through CFSE dilution after 3–5 days. (A) LILRB3 mAbs were deglycosylated (Degly) through PNGase treatment, as confirmed by SDS-PAGE; repre-
sentative clone A1 shown. (B) Assessing T cell activation and proliferation following treatment. Light microscopy images following PBMC stimulation 
in culture. CD8+ T cell proliferation was assessed through CFSE dilution; plots and images from a donor with profound A1-induced inhibition shown, 
histograms (% proliferation indicated) and microscopy images shown (original magnification, ×10). (C) Assessing the effects of deglycosylated LIL-
RB3 mAbs on T cell proliferation. CFSE dilution of CD8+ T cells, treated with the representative LILRB3 mAb, was assessed by flow cytometry. Data 
normalized to anti-CD3/CD28–treated samples and mean represented by solid bars. One-way ANOVA performed (**P < 0.005; ***P < 0.0005); n = 
13–20 independent donors (each color represents an individual donor).
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data show that LILRB3 activation results in significant phenotypic and transcriptional alterations in human 
primary myeloid cells, leading to potent inhibition of  downstream immune responses.
Discussion
We previously demonstrated that ligation of  LILRB1 on human DCs induces a tolerogenic phenotype, 
hindering T cell responses (18, 40). In this study, we investigated another inhibitory LILR family mem-
ber, LILRB3, whose function, largely due to lack of  suitable reagents and experimental systems, is not 
yet fully determined. Limited previous studies investigated the consequences of  LILRB3 ligation on 
granulocytes and have demonstrated its inhibitory function on neutrophils (41) and basophils (42) in 
culture. Here, we largely concentrated on myelomonocytic cells and the subsequent regulation of  adap-
tive immune responses. We, therefore, initially generated and characterized an extensive panel of  fully 
human mAbs with specificity for LILRB3 through a number of  stringent panning and selection processes. 
Figure 4. LILRB3 ligation induces tolerance in vivo. (A) Schematic of the generation of humanized mice and subsequent treatment regimens and mon-
itoring. (B) Expression of LILRB3 on human myeloid cells in humanized mice. Representative flow cytometry plots (gated on live single cells) showing 
gating strategy and the restricted expression of LILRB3 on hCD45+ peripheral blood hCD14+ myeloid cells; isotype control in pink and LILRB3 mAb staining 
depicted in blue. (C) The effect of agonistic LILRB3 mAb on engraftment of allogeneic cells in humanized mice. Age- and sex-matched humanized mice 
were injected with 200 μg LILRB3 mAb (clone A1) or an isotype-matched (hIgG1) control mAb (iso ctrl) on day 0 and 4, i.v. and i.p., respectively. On day 7, 
mice were injected i.p. with 1 × 107 nonautologous luciferase+ human lymphoma cells. Lymphoma cell growth was monitored over time using an IVIS imag-
er, and (D) humanized mice were sacrificed upon the development of signs of terminal tumor development. Survival data were analyzed using log-rank 
test (*P < 0.01); representative data from 3 independent experiments (3 individual HSPC donors) shown (n = 3 mice/group).
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Those clones showing cross-reactivity to other human LILR family members were excluded. Immuno-
profiling of  circulatory leukocytes from healthy donors using these highly specific mAbs confirmed the 
reported expression of  LILRB3 on myelomonocytic and granulocytic cells, but not on lymphocytes (2, 
3, 6). This pattern of  expression on myeloid and granulocytic but not lymphoid cells was confirmed 
in a large cohort of  independent donors (>50), suggesting that, despite the polymorphic nature of  
LILRB3 (2, 9, 43), the selected antibodies recognize many, if  not all, variants, which is important for 
the development of  these reagents for therapeutic applications. Subsequent analysis showed that the 
LILRB3 mAbs displayed a range of  affinities, albeit all within the nanomolar (nM) range, with similar 
on rates, but off  rates differing over 3 orders of  magnitude. KD values in the low nanomolar range are 
generally considered viable drug candidates; rituximab, for example, has an 8 nM affinity for its target, 
CD20 (44). This suggests that the LILRB3 mAbs generated here have potential as therapeutic agents. 
However, because LILRB3 shares high sequence homology (>95%) in its extracellular domain with 
LILRA6, there is a possibility that our LILRB3 mAbs may also recognize shared epitopes on LILRA6, 
if  coexpressed (9). These initial data might receive further evidence from other reagents as well as 
investigation as to whether LILRA6 protein is detectable in leukocyte subsets, e.g., using proteomics 
approaches similar to a recent study with neutrophils (41). Epitope-mapping experiments revealed that 
the specific LILRB3 mAbs reported herein were generated against 2 specific ectodomains, either Ig-like 
domain 2 or 4. Interestingly, none of  the generated specific LILRB3 mAbs bound to Ig-like domain 1 or 
3, suggesting that these domains may not contain epitopes that are unique for LILRB3, or more likely 
those unique residues are not exposed/accessible. Collectively, these data confirm that our LILRB3 
mAbs will be useful tools for dissecting LILRB3’s molecular mechanisms and may additionally have 
therapeutic benefits in relevant pathologies.
The ability of  the LILRB3 mAbs to influence T cell responses was variable, with some inhibiting pro-
liferation, while others resulted in modest increases in proliferation, supportive of  agonistic or blocking 
properties, respectively. Similar to LILRB1 (17, 18, 21), these effects are likely through manipulations 
of  APCs, specifically monocytes, because they are the only cells expressing LILRB3 in the culture. In 
support of  this, the agonistic LILRB3 mAbs did not suppress T cell proliferation in the absence of  mono-
cytes. Binding epitopes influence the ability of  mAbs to modulate receptor function in many systems 
(35, 45), and so it was unsurprising to see LILRB3 mAbs capable of  differing functions. However, the 
D4-binding A1 mAb was a strong inhibitor of  proliferation, whereas other D4-binding mAbs (e.g., A28) 
had no significant effect. Therefore, domain-specific epitopes did not seem to correlate directly with 
LILRB3 mAb–mediated effector cell functions and may not be predictive of  LILRB3 mAb function per 
se. Further detailed analyses, e.g., surface alanine scanning mutagenesis (45) and/or structural studies, 
are required to define the specific extracellular epitopes engaged by the selected LILRB3 mAbs and to 
investigate their influence on receptor activity.
Our observations demonstrating immunoinhibitory activities downstream of  LILRB3 were further 
confirmed in the reconstituted humanized mouse model. In this system, where LILRB3 is present only on 
the hematopoietic cells, and predominantly monocytes, in the absence of  appreciable numbers of  neutro-
phils, ligation of  LILRB3 with an agonistic LILRB3 mAb before injection of  allogeneic lymphoma cells 
(36, 37) induced tolerance in vivo and enabled subsequent tumor cell engraftment. This demonstrates the 
Figure 5. Human LILRB3 ligation reprograms human primary myeloid cells. Freshly isolated human peripheral CD14+ monocytes were treated with an 
isotype control (iso ctrl) or a human LILRB3 mAb (clone A1) and then assessed. (A) Agonistic LILRB3 mAb (clone A1) affects monocyte morphology. Light 
microscopy images following overnight treatment of freshly isolated CD14+ monocytes with indicated mAbs in culture (original magnification, ×10; left 
panel). Images of treated monocytes were analyzed and length of monocytes quantified (right panel). A total of 200–500 individual cells were analyzed 
per image. Combined data from 3 independent donors shown; lines indicate median; 2-tailed paired t test performed (***P < 0.0001). (B) Transcriptomic 
analysis of LILRB3-treated monocytes reveals upregulation of M2-associated genes compared with controls. RNA was extracted from cells following mAb 
treatment (~18 hours) and subjected to RNA-Seq. Red depicts genes that were significantly upregulated, and green depicts genes that were significantly 
downregulated compared with isotype control–treated cells (n = 5–6 independent donors). (C) Ligation of LILRB3 on primary human CD14+ monocytes 
downregulated M1-associated genes. GSEA graph showing a significant enrichment for M1-polarizing genes in LILRB3-treated monocytes versus isotype 
control, respectively. UP; upregulated, normalized enrichment score (NES) = –1.68; family-wise error rate (FWER); P < 0.001. (D) qPCR analysis of selected 
genes following LILRB3 ligation on monocytes using an agonistic LILRB3 mAb (A1), a nonagonistic LILRB3 mAb (A28), or an isotype control (iso ctrl). Data 
were normalized to GAPDH mRNA levels and standardized to the levels of isotype control–treated monocytes. Fold difference data were log10 transformed. 
One-way ANOVA with Bonferroni’s multiple-comparisons test was performed (*P < 0.005). (E) GSEA showing negative correlation with IFN-γ (NES = –2.17; 
FWER P < 0.001), IFN-α (NES = –2.3; FWER P < 0.001), and allograft rejection (NES = –1.58; FWER P = 0.14) signaling elements and positive correlation 
with oxidative phosphorylation (NES = 2; FWER P < 0.001).
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capacity of  LILRB3 to exert profound immunosuppressive effects that may be exploited in therapeutic 
settings, such as autoimmunity and transplantation, where transient induction of  immune tolerance will be 
beneficial. Similar observations were previously reported using a LILRB1 transgenic mouse model, where 
interactions between LILRB1 and MHCI or HLA-G expanded MDSCs and prolonged allogenic graft sur-
vival in vivo (46, 47).
Although typically regarded as an orphan receptor, earlier studies suggest that LILRB3 may asso-
ciate with cytokeratin-associated proteins such as those exposed on necrotic cancer cells (30). Others 
have also identified angiopoietin-like protein 5 and bacteria, such as Staphylococcus aureus, as a source 
of  potential ligands (48, 49). Therefore, our data provide a strong mechanism of  action whereby such 
endogenous or pathogenic ligands may be able to subvert immune responses by ligating LILRB3 during 
an ongoing immune response.
To investigate the pathways and factors involved in LILRB3-mediated immunosuppression, we 
investigated the transcriptomic changes in isolated peripheral myeloid cells following LILRB3 liga-
tion. Over 100 genes were differentially regulated in primary human monocytes following LILRB3 
ligation, some of  which are known to be associated with M2-polarized macrophages (13, 50). Amphi-
regulin (AREG) was among the genes whose expression was markedly upregulated in LILRB3-ligated 
monocytes. AREG is an epidermal growth factor–like growth factor, responsible for inducing toler-
ance and immunosuppression, via various mechanisms, including enhancement of  Treg activity (51). 
Furthermore, AREG is overexpressed in tumor-associated DCs (52) and suppressive/M2 macrophages 
(53) and has been suggested to play a crucial role in immunosuppression and cancer progression (54). 
Similarly a number of  other candidates, e.g., activin A (55) and CD276 (56), known for their immuno-
suppressive functions in myeloid cells were induced upon LILRB3 ligation. Although not formally 
tested, LILRB3-induced production of  soluble factors, such as AREG, by myeloid cells may promote 
the expansion and suppressive capacity of  Tregs in the PBMC cultures. Similarly, the reported upreg-
ulation of  immunoinhibitory receptors, such as CD276 (B7-H3), upon LILRB3 ligation on myeloid 
cells may restrain the activation of  T cells and their proliferative capacity (56, 57). In addition, GSEA 
demonstrated that ligation of  LILRB3 on monocytes substantially affected a number of  key pathways 
and functions. Interestingly, LILRB3-ligated monocytes had a gene signature associated with oxidative 
phosphorylation, which is the metabolic pathway adapted by M2-polarized myeloid cells and is import-
ant for their immunosuppressive activities (39). Such LILRB3-inducible immunosuppressive receptors 
or soluble factors may be responsible for the suppression observed in our T cell assays and for the 
induction of  tolerance in the humanized mouse model. Our ongoing efforts aim to interrogate these 
findings further and define the mechanisms responsible for LILRB3-mediated suppression of  immune 
responses at molecular and cellular levels, e.g., via siRNA knockdown or neutralization of  AREG in 
monocyte cultures and validation of  differentially regulated genes in the humanized mouse models. A 
recent study investigating the mode of  action of  glatiramer acetate (Copaxone), a peptide-based drug 
licensed in the late 1990s, used to treat patients with the relapsing-remitting form of  multiple sclerosis 
that ameliorates autoimmunity, identified LILRB2 and LILRB3 as potential ligands (58). On the other 
hand, blocking human LILRB2 with antagonistic mAbs on human myeloid cells is able to promote 
their proinflammatory activity and enhance antitumor responses in preclinical models (58); a LILRB2 
mAb (MK-4830) recently entered phase I clinical trials (ClinicalTrials.gov NCT03564691) for advanced 
solid tumors. Furthermore, recent data by Zhang and colleagues suggest that LILRB4 signaling in leu-
kemia cells mediates T cell suppression and supports tumor cell dissemination to distal organs (59). 
These recent compelling reports further support our findings, demonstrating that ligation of  human 
LILRB3 induces immunosuppression via reprogramming of  myeloid cells (i.e., reducing M1-like matu-
ration and promoting suppressive function).
In conclusion, we generated a specific panel of  human LILRB3 mAbs, binding to unique residues 
located within ectodomain 2 or 4, and used the strongest agonistic clone (A1) to reveal LILRB3’s potent 
immunoregulatory functions on myeloid cells using bespoke preclinical models. Our data demonstrated 
that LILRB3 engagement on primary human myeloid cells exerts potent immunoinhibitory functions 
and that LILRB3-specific mAbs are potentially powerful immunomodulatory agents, with broad applica-
tions ranging from transplantation to autoimmunity and beyond, where fine-tuning of  immune responses 
through myeloid cell activity is desired.
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Methods
Cell culture
Cell lines were grown at 37°C in RPMI 1640 medium supplemented with 10% heat-inactivated fetal calf  
serum (FCS) (MilliporeSigma), 100 U/mL penicillin-streptomycin, 2 mM glutamine, and 1 mM pyruvate 
(Thermo Fisher Scientific) in a humidified incubator with 5% CO2, FreeStyle 293F medium, in 8% CO2, 
shaken at 130 rpm, or FreeStyle CHO medium (Thermo Fisher Scientific) with 8 mM glutamine, in 8% 
CO2, shaken at 140 rpm.
Antibody generation and production
Generation of  LILRB3 antibodies. Generation of  LILRB3-specific mAbs was performed using the n-CoDeR 
phage-display library (28). Three consecutive panning rounds were performed, as well as a prepanning step. 
In the panning, human (h) Fc fusion proteins containing the extracellular domains of  LILRB1 and LILRB3 
(LILRB-hFc) were used as “nontarget” or “target,” respectively. These proteins were produced in tran-
siently transfected HEK293F cells (ATCC) followed by purification on protein A, as described previously 
(35). CHO-S cells (ATCC) transiently transfected to express the various LILRB proteins were also used as 
targets/nontargets in the panning.
In panning 1, BioInvent n-CoDeR scFv were selected using biotinylated in-house–produced recombi-
nant LILRB3-hFc fusion proteins (captured with streptavidin-coated Dynabeads, Thermo Fisher Scientific) 
with or without competition or LILRB1-hFc coated onto etched polystyrene balls (Polysciences) or plastic 
immunotubes. Binding phages were eluted by trypsin digestion and amplified on plates using standard pro-
cedures (60). The amplified phages from panning 1 were used for panning 2, the process repeated, and the 
amplified phages from panning 2 used in panning 3. In the third panning round, however, amplified phages 
from all 3 strategies were combined and selected against LILRB-expressing CHO-S cells, before making the 
final LILRB3-specific mAb selection.
Next, the LILRB3-positive scFv from the enriched phage repertoires from panning 3 were sub-
cloned to allow soluble scFv expression in E. coli. The soluble scFvs expressed by individual clones 
were tested for binding against LILRB-transfected CHO-S cells using FMAT and recombinant LIL-
RB protein by ELISA. This allowed the identification of  clones binding specifically to LILRB3. 
Clones were then further reduced in a tertiary screen against CHO-S cells expressing LILRB1–3 and 
primary cells (PBMCs) using a high-throughput flow cytometry screening system, with data analyzed 
by TIBCO Spotfire software (TIBColorado). Clones showing specific patterns of  binding to LILRB3 
were sequenced, yielding LILRB3-specific mAbs.
Production of  full-length IgG. The unique scFv identified above were cloned into a eukaryotic expression 
system allowing transient expression of  full-length IgG in HEK293-EBNA cells. The antibodies were then 
purified from the culture supernatants using Protein A affinity chromatography as previously described (35).
Production of  deglycosylated IgG. To allow dissection of  Fc- and F(ab′)-dependent effector functions, IgGs 
were deglycosylated using PNGase F (Promega) with 0.05 U PNGase/μg IgG, at 37°C for at least 15 
hours. Deglycosylation was confirmed by reduction in size of  the heavy chain on SDS-PAGE.
Production of domain mutant constructs
Using WT LILRB3 cDNA isolated from healthy donor PBMCs, a series of  domain-mutant DNA con-
structs were generated by overlap PCR to express 1, 2, or 3 LILRB3 Ig-like domains (with domains iden-
tified based on annotations in UniProt) for comparison to WT LILRB3 (4 domains). The gene constructs 
were then cloned into pcDNA3.
Cell transfections
HEK293F cells (1 × 107) were transiently transfected with 10 μg of  plasmid DNA by lipofection using 233 
fectin with Opti-Mem 1 Media (Thermo Fisher Scientific).
Preparation of human leukocytes
PBMCs were isolated from leukocyte blood cones (Blood Transfusion Services, Southampton General 
Hospital) by gradient density centrifugation using lymphoprep (Axis-Shield) and used for subsequent 
experiments, as before (61).
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Flow cytometry
For cell surface staining, human PBMCs, whole blood, or leukocytes from humanized mice were blocked 
with 10% human AB serum (MilliporeSigma) for 10 minutes on ice and then stained with the relevant 
APC-labeled LILRB3 mAb or hIgG1 isotype (BioInvent), alongside the following cell surface markers: 
human CD14-PE (clone 61D3; eBioscience, Thermo Fisher Scientific), CD20-A488 (rituximab; in-house), 
CD3-PE-Cy7 (clone HIT3a), CD56-APC-Cy7 (clone 5.1H11) or CD15-Pacific Blue (clone HI98), CD15-
PE and CD66B-FITC (clone G10F5), CD45-APC-Cy7 (clone 2D1), and mouse CD45.1-PerCP (clone 
A20) (all BioLegend). Cells were stained for 30 minutes at 4°C and then washed twice, first in 10% red 
blood cell (RBC) lysis buffer (Serotec) for PBMCs or 1× Erythrolyse RBC Lysing Buffer (Bio-Rad) for 
whole blood, then with FACS wash (PBS, 1% BSA, 10 mM NaN3), before acquisition on a FACSCalibur or 
FACSCanto II (BD Biosciences) and analysis with FlowJo software (BD Biosciences).
For assays to determine if  mAbs bound to similar cross-blocking epitopes, 1 × 106 PBMCs were blocked 
with 2% human AB serum for 10 minutes and stained with 10 μg/mL unconjugated LILRB3 mAbs for 30 min-
utes at 4°C. The cells were then stained with directly conjugated LILRB3 mAbs (clone 222821; mouse IgG2a; 
R&D Systems, Bio-Techne) for 20 minutes at 4°C, before washing and acquisition using a FACSCalibur.
For LILRB3 epitope-mapping studies, LILRB3 domain-mutant-transfected HEK293F cells were 
stained with the relevant LILRB3 mAb for 25 minutes at 4°C, washed twice, stained with an anti–human-
PE secondary antibody (109-116-170 Jackson ImmunoResearch) for 20 minutes at 4°C, before washing and 
acquisition using a FACSCalibur.
For staining of  2B4 reporter cells expressing LILR-A1, -A2, -A5, -B1, -B2, -B3, -B4, or -B5 (or non-
transfected controls) (30, 62), cells were stained with 10 μg/mL LILRB mAb and incubated at 37°C with 
5% CO2, overnight. The following day, the cells were washed and stained with a secondary anti-hIgG 
antibody (Jackson ImmunoResearch) at 4°C, for 45 minutes. The cells were washed and acquisition was 
performed using a FACScan (BD Biosciences), with data analyzed with FlowJo software.
Surface plasmon resonance
SPR was performed with the Biacore T100 (GE Healthcare) as per the manufacturer’s instructions. LILRB3-hFc 
recombinant protein (extracellular LILRB3 domain with an hFc tag) was used as the ligand and immobilized 
by amine coupling onto a series S sensor chip (CM5). Various LILRB3 mAbs were used as analytes and flowed 
across the chip, and SPR was measured. KD values were calculated from the Univalent model of 1:1 binding by 
Kd[1/s]/Ka[1/Ms], using the Biacore T100 Evaluation Software (GE Healthcare).
T cell proliferation assay
PBMCs (1 × 107 to 2 × 107) were labeled with 2 μM CFSE at room temperature for 10 minutes. An equal vol-
ume of  FCS was then added to quench labeling for 1 minute, before washing. Cells were subsequently resus-
pended in serum-free CTL medium (Immunospot) and plated at 1 × 105 cells/well in a 96-well round-bot-
tom plate (Corning). Cells were then stimulated with 0.02 μg/mL CD3 (clone OKT3, in-house), 5 μg/mL 
CD28 (clone CD28.2; BioLegend), and 10 μg/mL LILRB3 antibodies or a relevant isotype. Plates were 
then incubated at 37°C for 4 days, after which time cells were stained with 5 μg/mL CD8-APC (clone SK1; 
BioLegend), harvested and CFSE dilution measured by flow cytometry, as a readout for T cell proliferation.
HSPC isolation and generation of humanized mice
Humanized mice were generated, as described (36). In brief, human fetal livers were obtained from abort-
ed fetuses at 15–23 weeks of  gestation, in accordance with the institutional ethical guidelines (Advanced 
Bioscience Resources, Inc.). All women gave written informed consent for the donation of  their fetal 
tissue for research. Fresh tissue was initially cut into small pieces and digested with collagenase VI (2 
mg/mL; Roche) for 30 minutes at 37°C. Single-cell suspensions were prepared by passing the digested 
tissue through a 100 μm cell strainer (BD Biosciences). HSPCs were purified using a CD34+ selection kit 
(STEMCELL Technologies); the purity of  CD34+ cells was 90%–99%, as verified by CD34-PE (clone 561, 
BioLegend) immunophenotyping. Viability was determined through trypan blue exclusion of  dead cells. 
All cells were isolated under sterile conditions and injected into NOD/SCID IL-2Rγ–/– (NSG) mice.
NSG mice were purchased from The Jackson Laboratory and maintained under specific pathogen–free 
conditions in the animal facilities at Massachusetts Institute of  Technology (MIT). To reconstitute mice, 
newborn pups (less than 2 days old) were irradiated with 100 cGy using a gamma radiation source and 
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injected intracardially with CD34+ cells (~2 × 105 cells/recipient), as reported previously (36). Around 12 
weeks later, human leukocyte cell reconstitution of  PBMCs was determined by flow cytometry and calcu-
lated as follows: % human CD45+ cells/(% human CD45+ cells + % mouse CD45.1+ cells). Mice with at 
least 40% human CD45+ leukocytes were used in subsequent experiments.
In vivo allograft assay
Fully reconstituted humanized mice were injected with 200 μg LILRB3 mAb (clone A1) or an iso-
type-matched (hIgG1) control on day 0 and day 4, i.v. and i.p., respectively. On day 7, cohorts of  mice were 
injected i.p. with 1 × 107 luciferase-positive human “double-hit” B cell lymphoma cells (36, 37), derived 
from unrelated donors. Lymphoma cell growth was monitored over time using an IVIS Spectrum biolu-
minescent imaging system, as before (36). Mice with palpable tumors were sacrificed and Kaplan-Meier 
survival curves plotted.
Transcriptome analysis of treated monocytes
To assess LILRB3-mediated transcriptional changes on monocytes, human PBMCs were isolated from 
freshly prepared PBMCs taken from healthy donors using an EasySep Human Monocyte Enrichment 
Kit (negative selection cell; STEMCELL Technologies). Cells were incubated in CTL medium (Cellu-
lar Technology Limited) supplemented with 100 U/mL penicillin-streptomycin, 2 mM glutamine, and 
HEPES buffer and treated with 10 μg/mL of  an isotype control or an agonistic LILRB3 mAb (clone A1; 
hIgG1). Eighteen hours later, cells were lysed in RLT lysis buffer (QIAGEN) containing β-mercaptoeth-
anol, and total RNA was extracted using the RNeasy Micro Kit (QIAGEN). Total RNA was assessed for 
quality and quantified using a total RNA 6000 Nano LabChip on a 2100 Bioanalyzer (Agilent Inc.), and 
cDNA libraries were prepared and sequenced according to the Illumina TruSeq RNA Sample Prepara-
tion Guide for SMARTer Universal Low Input RNA Kit (Clontech) and a HiSeq 2000 system (Illumina). 
RNA-Seq outputs were aligned to hg19 using Bowtie2 v2.2.3 (63). The number of  mapped reads was 
quantified by RSEM v1.2.15 (64). Differential expression analysis between paired samples before and 
after treatment was performed using edgeR (65) with P < 0.05 and >2 fold change cutoffs. Differentially 
expressed genes were annotated using the online functional enrichment analysis tool Database for Anno-
tation, Visualization and Integrated Discovery (http://david.ncifcrf.gov/) (66). GSEA was performed 
using Broad Institute Software (67), with the gene list preranked according to log fold change values from 
the edgeR output. For comparison of  gene set expression, M1 and M2 macrophage gene sets (50) were 
obtained from the Molecular Signature Database (http://software.broadinstitute.org/gsea/msigdb/). 
Heatmaps were visualized with MeV (68). Raw sequences have been deposited in the National Center 
for Biotechnology Information’s Gene Expression Omnibus with accession ID GSE151675.
Quantification of monocyte length
Human PBMCs were isolated as indicated above and then cultured for approximately 18 hours in 6-well 
plates in the presence of  either isotype control or LILRB3 mAb (clone A1). Images were captured on an 
Olympus CKX41 inverted microscope, running under Olympus cellSens Standard software (version 2.1), and 
analyzed using ImageJ software (NIH). Length (μm) of monocytes was measured using the fragmented line 
tool, with the criterion of  a maximum of 5 fragmented lines and exclusion of  dead cells and cells found on the 
edges of  the images. A total of  200–500 individual cell lengths were quantified from 3 independent donors.
qPCR of treated monocytes
Probe-based qPCR was used to amplify cDNA in 20 μL reactions performed in triplicate for each sam-
ple condition in a PCR plate (Bio-Rad), as per the manufacturer’s protocol. The 96-well plate was run 
on a C1000 Thermal Cycler CFX96 Real-Time PCR System machine (Bio-Rad). CFX manager software 
(Bio-Rad) was used for data acquisition and analysis of  gene expression initially recorded as cycle thresh-
old values (Ct). The Ct values were normalized to housekeeping gene GAPDH and standardized to gene 
expression levels in isotype control–treated samples.
Statistics
One-way ANOVA was performed for both the human leukocyte immunophenotyping and T cell pro-
liferation data; straight bars indicate median values. On bar graphs, where at least 3 experiments were 
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performed, error bars represent standard deviation. Kaplan-Meier plots were analyzed by log-rank test. 
One-way ANOVA with Bonferroni’s multiple-comparisons test were performed for qPCR data analysis. 
Statistical analysis was performed using GraphPad Prism (v6-8). P < 0.05 was considered significant.
Study approval
All research with human samples and mice was performed in compliance with institutional guidelines, 
the Declaration of  Helsinki, and the US Department of  Health and Human Services Guide for the Care 
and Use of  Laboratory Animals (National Academies Press, 2011). The Committee on Animal Care at 
MIT reviewed and approved the studies described here. All human samples (adult peripheral blood 
and fetal liver) were collected anonymously with informed consent by a third party and purchased for 
research. For human peripheral blood, ethical approval for the use of  clinical samples was obtained by 
the Southampton University Hospitals NHS Trust, from the Southampton and South West Hampshire 
Research Ethics Committee following provision of  informed consent.
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